Top Markets
#1 ADO Protocol ADO Protocol +336.48%
#2 GoPlus Security GoPlus Security +50.52%
#3 Starpower Starpower +36.17%
#4 Fake World Assets Fake World Assets +29.96%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +26.56%
#6 GAIB AID GAIB AID +24.67%
#7 Nockchain Nockchain +22.31%
#8 The Black Bull The Black Bull +18.45%
#9 OpenEden OpenEden +14.53%
#10 Tutorial Tutorial +12.76%
Coin of the day
ADO Protocol ADO Protocol
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Traws Pharma, Inc. Traws Pharma, Inc.

Traws Pharma, Inc.

TRAW
Classifica tra le azioni #33205
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage,... Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
Prezzo delle azioni
$0.54
Capitalizzazione di mercato
$8.22M
Variazione (1 giorno)
-5.43%
Variazione (1 anno)
-64.24%
Paese
US
Scambia Traws Pharma, Inc. (TRAW)

Categoria

Healthcare
Ricavi di Traws Pharma, Inc. (TRAW)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Traws Pharma, Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Traws Pharma, Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE